• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中度帕金森病伴轻度运动波动。

Mid-stage parkinsonism with mild motor fluctuations.

作者信息

Tolosa E, Valldeoriola F

机构信息

Service of Neurology, Hospital Clinic i Provincial, Barcelona, Spain.

出版信息

Clin Neuropharmacol. 1994;17 Suppl 2:S19-31.

PMID:9358192
Abstract

Most patients with Parkinson's disease who undergo levodopa therapy eventually develop fluctuations in the diurnal control of their symptoms. These fluctuations, when mild, consist mostly of the "wearing-off" effect--the re-emergence of symptoms several hours after the ingestion of each dose of levodopa. In some patients, "wearing-off" in the daytime is preceded by, or associated with, the development of nocturnal and early morning akinesia. Some patients at this stage also have mild (mostly peak dose or square-wave) choreoathetoid dyskinesias. In patients with "wearing-off," "on" periods tend to occur when plasma levels of levodopa are high; nocturnal and early morning akinesia and diurnal "off" periods tend to occur at times when plasma levodopa levels are low, reflecting insufficient concentrations of dopamine in the striatum. Treatment strategies in patients with mid-stage parkinsonism and mild fluctuations are primarily directed toward enhancing dopaminergic transmission in the striatum. This is achieved by increasing the supply of levodopa to the brain or by administering drugs that either prolong the effect of synaptic dopamine from levodopa, or activate postsynaptic dopamine receptors. This presentation will discuss the advantages and possible drawbacks of these different strategies, which include the use of controlled-release levodopa preparations, deprenyl, and the new monoamine oxidase (MAO)-B inhibitors, catechol-O-methyl transferase (COMT) inhibitors, and the various "direct" dopamine agonists.

摘要

大多数接受左旋多巴治疗的帕金森病患者最终会出现症状日间控制的波动。这些波动在轻度时,主要表现为“剂末现象”——每次服用左旋多巴数小时后症状重新出现。在一些患者中,日间“剂末现象”之前或与之相关的是夜间和清晨运动不能的出现。在这个阶段,一些患者还会出现轻度(主要是峰剂量或方波)舞蹈手足徐动样运动障碍。在有“剂末现象”的患者中,“开”期往往出现在左旋多巴血浆水平较高时;夜间和清晨运动不能以及日间“关”期往往出现在血浆左旋多巴水平较低时,这反映了纹状体内多巴胺浓度不足。中期帕金森病且波动较轻患者的治疗策略主要是增强纹状体内的多巴胺能传递。这可以通过增加左旋多巴向脑内的供应,或通过给予能延长左旋多巴突触多巴胺作用或激活突触后多巴胺受体的药物来实现。本报告将讨论这些不同策略的优点和可能的缺点,这些策略包括使用控释左旋多巴制剂、司来吉兰以及新型单胺氧化酶(MAO)-B抑制剂、儿茶酚-O-甲基转移酶(COMT)抑制剂和各种“直接”多巴胺激动剂。

相似文献

1
Mid-stage parkinsonism with mild motor fluctuations.中度帕金森病伴轻度运动波动。
Clin Neuropharmacol. 1994;17 Suppl 2:S19-31.
2
Treatment of levodopa-induced motor complications.左旋多巴诱发的运动并发症的治疗。
Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052.
3
Other pharmacological treatments for motor complications and dyskinesias.针对运动并发症和异动症的其他药物治疗方法。
Mov Disord. 2005;20 Suppl 11:S38-44. doi: 10.1002/mds.20462.
4
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.优化药物治疗:应对疗效减退现象的策略
J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):12-7.
5
New and emerging strategies for improving levodopa treatment.改善左旋多巴治疗的新策略和新兴策略。
Neurology. 1994 Jul;44(7 Suppl 6):S35-44.
6
Treatment strategies for extension of levodopa effect.左旋多巴疗效延长的治疗策略。
Neurol Clin. 1992 May;10(2):511-26.
7
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.帕金森病运动波动的突触前机制:一个概率模型
Brain. 2004 Apr;127(Pt 4):888-99. doi: 10.1093/brain/awh102. Epub 2004 Feb 11.
8
Off spells and dyskinesias: pharmacologic management of motor complications.发作和运动障碍:运动并发症的药物治疗管理。
Cleve Clin J Med. 2012 Jul;79 Suppl 2:S8-13. doi: 10.3949/ccjm.79.s2a.02.
9
Parkinson's disease therapy: treatment of early and late disease.帕金森病治疗:早期和晚期疾病的治疗
Chin Med J (Engl). 2001 Mar;114(3):227-34.
10
Various aspects of motor fluctuations and their management in Parkinson's disease.帕金森病中运动波动的各个方面及其管理
Neurology. 1994 Jul;44(7 Suppl 6):S29-34.